(Q57484110)

12

object named as

Christopher B. Granger

0 references

Kenneth W Mahaffey

2

object named as

Kenneth W. Mahaffey

0 references

W. Douglas Weaver

6

object named as

W. Douglas Weaver

0 references

author name string

Abhinav Goyal

1

0 references

Jyotsna Garg

3

0 references

Jose C. Nicolau

4

0 references

Judith S. Hochman

5

0 references

Pierre Theroux

7

0 references

Gustavo B.F. Oliveira

8

0 references

Thomas G. Todaro

9

0 references

Christopher F. Mojcik

10

0 references

Paul W. Armstrong

Impaired glucose metabolism predicts mortality after a myocardial infarction

11

0 references

publication date

12 April 2006

0 references

published in

European Heart Journal

0 references

volume

27

0 references

issue

11

0 references

page(s)

1289-1297

0 references

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

The prognostic value of blood glucose in diabetic patients with acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

In-hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Short-term mortality of myocardial infarction patients with diabetes or hyperglycaemia during admission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Prognostic value of admission glucose in non-diabetic patients with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise th

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

American College of Endocrinology position statement on inpatient diabetes and metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Follow-up report on the diagnosis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI884